Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- IL6R? CD-126 IL6 gp-130 STAT-3 sIL6R? antiinflammatory proinflammatory Covid19 rhPM1 PM1 IL6R-A gp-80
- Product Overview:
Interleukin-6R? (IL-6R?), also known as CD126, is a type I cytokine receptor.{16580} It is composed of an immunoglobulin-like domain, a cytokine-binding domain, a transmembrane domain, and a cytoplasmic domain and forms a heteromeric complex with IL-6 and gp130, which is the signal transducing subunit of the IL-6R that primarily acts through the JAK/STAT3 pathway.{65404} IL-6R? is expressed in hepatocytes and monocytes and is localized to the plasma membrane but also exists as a soluble form (sIL-6R?) that is primarily generated via proteolytic cleavage of membrane-bound IL-6R?, but can also be formed via alternative splicing.{65405,65406,65407} Binding of IL-6 to membrane-bound IL-6R?, known as classical signaling, upregulates the synthesis of acute phase proteins, induces lipolysis in the liver, and induces the differentiation of T and B cells and is primarily anti-inflammatory.{46747,46748} Trans-signaling consists of IL-6 binding to sIL-6R, which has various pro-inflammatory effects. Knockdown of IL6R increases sensitivity to tamoxifen in breast cancer cells.{65408} Formulations containing chimeric anti-IL-6R? monoclonal antibodies have been used in the treatment of rheumatoid arthritis, idiopathic arthritis, giant cell arteritis, cytokine release syndrome, and COVID-19. Cayman’s Interleukin-6R?/CD126 Chimeric Monoclonal Antibody was produced recombinantly from the original rhPM-1 antibody and can be used for ELISA. The rhPM-1 antibody was generated by CDR grafting of mouse PM-1 antibody onto human REI and NEW framework regions.{69140}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.